At the SHEA conference in Linköping, NHTA hosted a panel on the EU JCA’s impact on Sweden’s HTA system. Experts from TLV, LIF, and NHTA stressed the importance of communication to avoid delays in patient access under the new joint assessment process.
Insights
Impact of JCA on Sweden’s HTA system?
At the annual SHEA (Swedish Health Economics Association) conference in Linköping, we hosted a panel to discuss this pressing question with Hanna Zirath, Ph.D., Emma Sabelström, Mikael Svensson, Andreas Pagh, and Thomas Kristensen, bringing together diverse perspectives from The Dental and Pharmaceutical Benefits Agency, TLV, The Swedish Association of the Pharmaceutical Industry, LIF, and NHTA.
The discussion highlighted both the opportunities and risks the new JCA process presents for Sweden. A key takeaway was that communication is essential for all stakeholders to ensure that the EU JCA will not delay patients access to new treatments in Sweden.
Thank you to our panellists, SHEA organisers, and all attendees for a successful conference!
Want to hear more about the EU JCA and impact on Sweden’s HTA system? Reach out to Andreas Pagh: ap@nhta.com
